Moderna, Pfizer Protocols May Make COVID Vaccine Candidates Hard to Compare

While Operation Warp Speed is trying to harmonize coronavirus study designs, Pfizer’s go-it-alone approach may make its vaccine hard to compare to others.

Render illustration of Clinical Trial title on medical documents
Details of the first late-stage trials of COVID-19 vaccine canddiates were revealed this week • Source: Shutterstock

It will be difficult to compare Moderna, Inc. and Pfizer Inc.’s coronavirus vaccines based on their Phase III study designs, some vaccines experts said.

“Both trials appeared to be well designed,” based on publicly available information, said Ira Longini, co-director of the Center for...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Vaccines

More from Pink Sheet